Share Name Share Symbol Market Type
Merck and Co Inc NYSE:MRK NYSE Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  -0.72 -0.92% 77.45 78.655 77.15 77.81 11,591,631 00:45:00

Merck Gets EU Approval for Keytruda in Classical Hodgkin Lymphoma

17/03/2021 11:47am

Dow Jones News

Merck (NYSE:MRK)
Historical Stock Chart

From Mar 2021 to May 2021

Click Here for more Merck Charts.

By Colin Kellaher


Merck & Co. on Wednesday said the European Commission approved the expanded use of its cancer drug Keytruda in adults and children with relapsed or refractory classical Hodgkin lymphoma.

The Kenilworth, N.J., drugmaker said the approval covers Keytruda as a monotherapy for patients ages 3 and older who have failed autologous stem cell transplant or following at least two prior therapies when transplant isn't a treatment option.

Merck said the approval marks the first pediatric indication in the European Union for Keytruda, which harnesses a patient's immune system to fight tumors.

Classical Hodgkin lymphoma accounts for more than 90% of cases of Hodgkin lymphoma, a cancer of the lymphatic system, which is part of the immune system.


Write to Colin Kellaher at


(END) Dow Jones Newswires

March 17, 2021 07:32 ET (11:32 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

1 Year Merck Chart

1 Year Merck Chart

1 Month Merck Chart

1 Month Merck Chart
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210512 03:16:07